

78. The isolated HLA class II-binding peptide of claim 5 wherein the endosomal targeting signal comprises an endosomal targeting portion of human invariant chain Ii or LAMP-1.

79. The isolated HLA class II-binding peptide of claim 7 wherein the isolated peptide is selected from the group consisting of peptides comprising D-amino acids, peptides comprising a -psi[CH₂NH]-reduced amide peptide bond, peptides comprising a -psi[COCH₂]-ketomethylene peptide bond, peptides comprising a -psi[CH(CN)NH]-(cyanomethylene)amino peptide bond, peptides comprising a -psi[CH₂CH(OH)]-hydroxyethylene peptide bond, peptides comprising a -psi[CH₂O]-peptide bond, and peptides comprising a -psi[CH₂S]-thiomethylene peptide bond.

80. The composition of claim 9 wherein the MAGE-A1 HLA class I-binding peptide and the MAGE-A1 HLA class II-binding peptide are combined as a polytope polypeptide.

81. The composition of claim 11 wherein the isolated MAGE-A1 HLA class II-binding peptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7.

82. The composition of claim 11 wherein the isolated MAGE-A1 HLA class II-binding peptide consists of an amino acid sequence selected from the group consisting of SEQ ID NO:3, SEQ ID NO:4 and SEQ ID NO:7.

83. The composition of claim 14 wherein the endosomal targeting signal comprises an endosomal targeting portion of human invariant chain Ii or LAMP-1.

REMARKS

Please enter this Preliminary Amendment examining the claims. Applicants have added claims corresponding to claims 3, 4, 6, 8, 10, 12, 13 and 15, which previously were canceled. No new matter has been added.

Applicants understand that certain of these claims contain species other than the species elected in the response to the restriction requirement filed herewith. Applicants are presenting